Phase II study of weekly irinotecan (CPT-11) associated to protracted oral tegafur (TGF) in previously untreated, advanced colorectal cancer (ACRC)

被引：0
|
作者：
Saigi, E
Batiste-Alentorn, E
Diaz, N
Galan, A
Salud, A
Campos, JM
Losa, F
Gallen, M
Massuti, B
Asensio, D
机构：
[1] Consorci Sanitari Parc Tauli, Sabadell, Spain
[2] Hosp Gen Vic, Vic, Spain
[3] Hosp Virgen Arreixaca, El Palmar, Spain
[4] Hosp Sagunto, Puerto Sagunto, Spain
[5] Hosp Univ Arnua Vilanova, Lleida, Spain
[6] Hosp Arnau Vilanova, Valencia, Spain
[7] Hosp Lhospitalet, Lhospitalet De Llobregat, Spain
[8] Hosp Mar, Barcelona, Spain
[9] Hosp Gen Univ Alicante, Alicante, Spain
[10] Prasfarma Almirall, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：302S / 302S
页数：1
相关论文
共 50 条
  • [1] Phase II study of weekly irinotecan (CPT-11) as second-line treatment of patients with advanced colorectal cancer
    J. Cassinello
    P. López-Alvarez
    A. Martínez-Guisado
    M. Valladares
    G. Huidobro
    R. López
    U. Bohn
    I. Sevilla
    P. Ballesteros
    M. Jorge
    R. Pérez-Carrión
    J. L. Fernández
    J. Dorta
    Medical Oncology, 2003, 20 : 37 - 43
  • [2] Phase II study of weekly irinotecan (CPT-11) as second-line treatment of patients with advanced colorectal cancer
    Cassinello, J
    López-Alvarez, P
    Martínez-Guisado, A
    Valladares, M
    Huidobro, G
    López, R
    Bohn, U
    Sevilla, I
    Ballesteros, P
    Jorge, M
    Pérez-Carrión, R
    Fernández, JL
    Dorta, J
    MEDICAL ONCOLOGY, 2003, 20 (01) : 37 - 43
  • [3] A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma
    Rothenberg, ML
    Cox, JV
    DeVore, RF
    Hainworth, JD
    Pazdur, R
    Rivkin, SE
    Macdonald, JS
    Geyer, CE
    Sandbach, J
    Wolf, SL
    Mohrland, JS
    Elfring, GL
    Miller, LL
    Von Hoff, DD
    CANCER, 1999, 85 (04) : 786 - 795
  • [4] A bi-weekly schedule of irinotecan (CPT-11) and 5-fluorouracil (5-FU) in advanced colorectal cancer (ACRC): Phase I study.
    Morese, R
    Ricevuto, U
    Cannita, K
    Antonini, CGC
    Lanfiuti, BP
    Trapasso, T
    Porzio, G
    Marchetti, P
    Ficorella, C
    ANNALS OF ONCOLOGY, 2000, 11 : 71 - 71
  • [5] Phase II Study of S-1 Combined with Irinotecan (CPT-11) in Patients with Advanced Colorectal Cancer
    Tsunoda, A.
    Yasuda, N.
    Nakao, K.
    Narita, K.
    Watanabe, M.
    Matsui, N.
    Kusano, M.
    ONCOLOGY, 2009, 77 (3-4) : 192 - 196
  • [6] Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors
    Font, A
    Sanchez, JM
    Rosell, R
    Taron, M
    Martinez, E
    Guillot, M
    Manzano, JL
    Margeli, M
    Barnadas, A
    Abad, A
    LUNG CANCER, 2002, 37 (02) : 213 - 218
  • [7] Irinotecan (CPT-11) in combination with raltitrexed (TX) in patients with previously untreated, advanced colorectal cancer (ACC) patients.: Preliminary results of a phase I/II trial.
    Losa, F
    Manzano, H
    Vicente, P
    Rifa, J
    Ocaña, J
    Balcells, M
    Mediavilla, D
    Heras, L
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 288S - 288S
  • [8] Phase II trial of irinotecan (CPT-11) in patients with 5-FU resistant advanced colorectal cancer
    Vicent, JM
    Aparicio, J
    Lizon, J
    Molins, C
    Alonso, JD
    Gimenez-Arnau, JM
    Camps, C
    Segura, A
    Rizo, A
    Xarles, J
    ANNALS OF ONCOLOGY, 1998, 9 : 44 - 45
  • [9] A phase II study of irinotecan (CPT-11) and carboplatin in patients with previously untreated small cell lung cancer (SCLC):: Preliminary results.
    Amenedo, M
    Vázquez, F
    Lázaro, M
    Casal, J
    Mel, JR
    Antón, LM
    Firvida, JL
    Grande, C
    Castellanos, J
    Balcells, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 687S - 687S
  • [10] The current chemotherapy for advanced pancreatic cancer including the result of phase II study of irinotecan (CPT-11)
    Sumii, Toshihiko
    Fujimori, Nao
    Funakoshi, Akihiro
    PANCREAS, 2008, 37 (01) : 112 - 112
12345